Sugi Predict

Sugi Predict / Compounds / SCHEMBL803150

SCHEMBL803150

SCHEMBL803150

CCc1ccc(-c2ccc(CC)cn2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 9/20 0.69
▸ SMN1; SMN2 Q16637 9/20 0.69
▸ NPC1 O15118 7/20 0.69
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ NFKB1 P19838 2/20 0.54
▸ NFKB2 Q00653 2/20 0.54
▸ RELA Q04206 2/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ TP53 P04637 3/20 0.54
▸ METAP2 P50579 1/20 0.53
▸ MAPT P10636 5/20 0.51
▸ STAT3 P40763 1/20 0.51
▸ ATM Q13315 1/20 0.51
▸ CASP3 P42574 1/20 0.50
▸ SENP8 Q96LD8 1/20 0.50
▸ SENP7 Q9BQF6 1/20 0.50
▸ SENP6 Q9GZR1 1/20 0.50
▸ KDM4E B2RXH2 1/20 0.45
▸ MITF O75030 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10561342 0.94 SMN1; SMN2 (0.63) RAB9ASMN1; SMN2NPC1L3MBTL1NFKB1
SCHEMBL12684741 0.90 RAB9A (0.63) RAB9ASMN1; SMN2NPC1L3MBTL1NFKB1
SCHEMBL10553759 0.90 SMN1; SMN2 (0.58) RAB9ASMN1; SMN2NPC1L3MBTL1NFKB1
SCHEMBL8240137 0.88 SMN1; SMN2 (0.57) RAB9ASMN1; SMN2NPC1L3MBTL1NFKB1
SCHEMBL17954213 0.88 SMN1; SMN2 (0.66) RAB9ASMN1; SMN2NPC1L3MBTL1NFKB1
SCHEMBL152870 0.88 NPC1 (0.66) RAB9ASMN1; SMN2NPC1L3MBTL1NFKB1
SCHEMBL9602018 0.88 NPC1 (0.61) RAB9ASMN1; SMN2NPC1L3MBTL1NFKB1
SCHEMBL4943133 0.88 SMN1; SMN2 (0.62) RAB9ASMN1; SMN2NPC1L3MBTL1NFKB1
SCHEMBL12603839 0.88 SMN1; SMN2 (0.61) RAB9ASMN1; SMN2NPC1L3MBTL1NFKB1
SCHEMBL28079637 0.88 SMN1; SMN2 (0.71) RAB9ASMN1; SMN2NPC1L3MBTL1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043781-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2024-07-23 — — US disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 — — US disclosed
US-11873438-B2 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-01-16 — — US disclosed
US-20230357637-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2023-11-09 — — US disclosed
US-11802243-B2 Liquid-crystal medium MERCK PATENT GMBH (DE) 2023-10-31 — — US disclosed
US-20230340328-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2023-10-26 — — US disclosed
US-11788009-B2 Liquid-crystalline medium for use in a switching element MERCK PATENT GMBH (DE) 2023-10-17 — — US disclosed
US-20230323209-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2023-10-12 — — US disclosed
US-11781069-B2 Liquid-crystal medium MERCK PATENT GMBH (DE) 2023-10-10 — — US disclosed
US-20230313043-A1 OPTICAL COMPONENT MERCK PATENT GMBH (DE) 2023-10-05 — — US disclosed
US-20120328565-A1 ANTIVIRAL COMPOUNDS BRINKMAN JOHN A (US) 2012-12-27 — — US disclosed
US-20120230951-A1 ANTIVIRAL COMPOUNDS ALAM MUZAFFAR (US) 2012-09-13 — — US disclosed
US-20120182516-A1 POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-07-19 — — US disclosed
US-20120069289-A1 LIQUID CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-03-22 — — US disclosed
US-20120032112-A1 LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-02-09 — — US disclosed
US-20110261311-A1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL MEDIA AND LIQUID-CRYSTAL DISPLAYS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-10-27 — — US disclosed
US-20110255048-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2011-10-20 — — US disclosed
US-20110095229-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-04-28 — — US disclosed
US-20100272925-A1 LIQUID-CRYSTAL DISPLAY MERCK PATENT GESELLSCHAFT (DE) 2010-10-28 — — US disclosed
EP-0283490-B1 PROCESS FOR THE PRODUCTION OF ETHANE DERIVATIVES MERCK PATENT GmbH (DE) 1992-01-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110255048-A1 LIQUID-CRYSTAL DISPLAY KLK3, BPHL, LPXN RAB9A 1935/4885SMN1; SMN2 1049/4885NPC1 3791/4885
US-20120182516-A1 POLYMERIZABLE COMPOUNDS AND THEIR USE IN LIQUID-CRYSTAL DISPLAYS VCL, LPXN, ACP3 RAB9A 1526/4885SMN1; SMN2 914/4885NPC1 4177/4885
US-20100272925-A1 LIQUID-CRYSTAL DISPLAY KLK3, BPHL, LPXN RAB9A 1398/4885SMN1; SMN2 701/4885NPC1 3067/4885
US-20120328565-A1 ANTIVIRAL COMPOUNDS EIF2AK2, HAVCR2, MAVS RAB9A 883/4885SMN1; SMN2 3112/4885NPC1 108/4885
US-20120230951-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS RAB9A 2042/4885SMN1; SMN2 4272/4885NPC1 76/4885
US-20110261311-A1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL MEDIA AND LIQUID-CRYSTAL DISPLAYS LPXN, MAP1LC3C, VCL RAB9A 1114/4885SMN1; SMN2 1053/4885NPC1 4368/4885
US-20120069289-A1 LIQUID CRYSTAL DISPLAY LPXN, VCL, ACP3 RAB9A 2141/4885SMN1; SMN2 882/4885NPC1 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.